Centessa Pharmaceuticals Ownership | Who Owns Centessa Pharmaceuticals?


OverviewForecastRevenueFinancialsChart

Centessa Pharmaceuticals Ownership Summary


Centessa Pharmaceuticals is owned by 67.06% institutional investors, 0.53% insiders, and 32.41% retail investors. Medicxi ventures management (jersey) is the largest institutional shareholder, holding 14.88% of CNTA shares. Fidelity Select Biotechnology is the top mutual fund, with 1.51% of its assets in Centessa Pharmaceuticals shares.

CNTA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCentessa Pharmaceuticals67.06%0.53%32.41%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Medicxi ventures management (jersey)19.96M14.88%$499.28M
Avoro capital advisors10.81M8.09%$262.10M
Adage capital partners gp10.04M7.51%$243.35M
Index venture life associates vi9.96M7.43%$249.14M
General atlantic9.68M7.24%$234.78M
Fmr6.28M4.70%$152.22M
Janus henderson group4.91M4.22%$82.22M
Price t rowe associates inc /md/4.80M3.59%$116.50M
Farallon capital management4.33M3.24%$105.03M
First light asset management3.64M2.72%$88.17M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Index venture life associates vi9.96M100.00%$249.14M
Medicxi ventures management (jersey)19.96M59.80%$499.28M
Foresite capital management vi1.31M12.31%$31.86M
Allostery investments lp52.50K8.79%$689.85K
First light asset management3.64M8.31%$88.17M
General atlantic9.68M7.05%$234.78M
5am venture management680.95K6.05%$16.51M
Saturn v capital management734.54K3.91%$17.81M
Tcg crossover management3.14M3.74%$76.06M
Avoro capital advisors10.81M3.39%$262.10M

Top Buyers

HolderShares% AssetsChange
Avoro capital advisors10.81M3.39%5.81M
Janus henderson group4.91M0.04%3.61M
Fmr6.28M0.01%2.45M
Perceptive advisors3.10M2.17%1.95M
Adage capital partners gp10.04M0.39%1.63M

Top Sellers

HolderShares% AssetsChange
Vida ventures advisors---3.93M
Holocene advisors, lp---2.26M
Point72 asset management1.07M0.04%-1.52M
Baker bros. advisors lp---1.23M
Price t rowe associates inc /md/4.80M0.01%-1.10M

New Positions

HolderShares% AssetsChangeValue
Ecor1 capital550.00K0.64%550.00K$13.34M
Logos global management lp525.00K1.14%525.00K$12.73M
Wcm investment management257.19K0.01%257.19K$6.36M
Jain global241.97K0.03%241.97K$5.87M
Deutsche bank ag\156.21K0.00%156.21K$3.91M

Sold Out

HolderChange
Principal securities-17.00
Bell investment advisors-31.00
Caldwell sutter capital-43.00
Spire wealth management-70.00
Washington trust advisors-184.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025103-26.95%89,972,752-29.89%670.73%56-11.11%32-36.00%
Sep 30, 202514010.24%128,318,6543.84%951.11%62-11.43%5047.06%
Jun 30, 2025126-10.00%123,550,297-0.00%921.08%69-9.21%34-8.11%
Mar 31, 202514118.49%124,864,8700.36%930.82%7522.95%38-
Dec 31, 202411811.32%124,412,24014.59%1071.23%60-21.05%38137.50%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Fidelity Select Biotechnology2.23M1.51%-104.20K
T. Rowe Price Health Sciences2.19M1.48%-172.24K
Fidelity Select Health Care1.60M1.08%40.00K
Federated Hermes Kaufmann Growth1.24M0.84%350.70K
Federated Hermes Kaufmann R1.24M0.84%350.70K
American Funds SMALLCAP World A1.14M0.77%452.11K
Polar Capital Biotech S Inc1.00M0.75%-
Federated Hermes Kaufmann Small Cap A1.08M0.73%239.70K
Federated Hermes Kaufmann Small Cap Grow1.08M0.73%239.70K
Franklin Biotechnology Discv A(acc)USD1.06M0.72%-

Recent Insider Transactions


DateNameRoleActivityValue
Feb 02, 2026HUSSAIN IQBAL J Chief Legal OfficerSell$979.66K
Jan 30, 2026HUSSAIN IQBAL J Chief Legal OfficerSell$25.26K
Dec 09, 2025Accardi Mario Alberto President, Orexin ProgramSell$213.28K
Dec 09, 2025Accardi Mario Alberto President, Orexin ProgramSell$75.01K
Dec 08, 2025Accardi Mario Alberto President, Orexin ProgramSell$300.00K

Insider Transactions Trends


DateBuySell
2026 Q1-2
2025 Q4-8
2025 Q3-14
2025 Q2212
2025 Q1-18

CNTA Ownership FAQ


Who Owns Centessa Pharmaceuticals?

Centessa Pharmaceuticals shareholders are primarily institutional investors at 67.06%, followed by 0.53% insiders and 32.41% retail investors. The average institutional ownership in Centessa Pharmaceuticals's industry, Biotech Stocks , is 381.47%, which Centessa Pharmaceuticals falls below.

Who owns the most shares of Centessa Pharmaceuticals?

Centessa Pharmaceuticals’s largest shareholders are Medicxi ventures management (jersey) (19.96M shares, 14.88%), Avoro capital advisors (10.81M shares, 8.09%), and Adage capital partners gp (10.04M shares, 7.51%). Together, they hold 30.47% of Centessa Pharmaceuticals’s total shares outstanding.

Does Blackrock own Centessa Pharmaceuticals?

BlackRock is not among the top 10 institutional shareholders of Centessa Pharmaceuticals.

Who is Centessa Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Index venture life associates vi is Centessa Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 100.00% of its assets in 9.96M Centessa Pharmaceuticals shares, valued at 249.14M$.

Who is the top mutual fund holder of Centessa Pharmaceuticals shares?

Fidelity Select Biotechnology is the top mutual fund holder of Centessa Pharmaceuticals shares, with 1.51% of its total shares outstanding invested in 2.23M Centessa Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools